Gustave Roussy
Gustave Roussy is Europe's leading cancer centre, home of the ESMO-MCBS scale and major ADC and immunotherapy trial leadership.
Largest cancer centre in Europe; DITEP phase 1 unit; leadership of DESTINY, TROPION, and immunotherapy trials; Paris-Saclay affiliation.
- Phase 1 (DITEP)
- Breast ADC trials
- Immuno-oncology
Surgical oncologist who led the EORTC adjuvant ipilimumab and pembrolizumab trials in melanoma.
Aurélien Marabelle is the immunotherapy investigator behind the tumour-agnostic pembrolizumab data in MSI-high cancers.
Benjamin Besse is a lung cancer trialist central to the Dato-DXd and HER3-DXd lung programmes.
Breast cancer geneticist who led SOLAR-1 and the SAFIR precision-medicine trials; ESMO President 2025-2026.
Fabrice Barlesi runs Europe's largest cancer centre and is a leading lung cancer trialist.
Ran the phase 1 unit that pioneered many targeted therapies, and led the FLAURA trial that made osimertinib first-line.
Led LATITUDE and PEACE-1, which put abiraterone into first-line metastatic prostate cancer.
Immunologist who showed that the gut microbiome shapes responses to immunotherapy and chemotherapy.
Pages like this
not linked directly; found by shared links- InstitutionInstitut Curie
Shares Fondation ARC pour la recherche sur le cancer, Institut Pasteur, Haute Autorité de Santé, Institut National du Cancer.
- TechnologyFaecal microbiota transplantation for PD-1 non-responders
Shares Laurence Zitvogel, Microbiome transplant as a routine immunotherapy adjunct, Take faecal transplant plus immunotherapy to a definitive trial, Microbiome–tumour interactions.
- TrialFMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)
Shares Microbiome transplant as a routine immunotherapy adjunct, Take faecal transplant plus immunotherapy to a definitive trial, Microbiome–tumour interactions.
- InstitutionInstitut Bergonié
Shares Institut National du Cancer, UNICANCER, Sarcomas (soft tissue, bone, GIST).
- InstitutionMemorial Sloan Kettering Cancer Center
Shares A mandatory trial line in every tumour board recommendation, Give immunotherapy in the morning, A global first-in-human network for academic cancer trials with single ethics review, What actually holds T cells at the tumour border?.
- CompanyAstraZeneca
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Datopotamab deruxtecan, Trastuzumab deruxtecan, Thyroid cancer.
- PathwayPD-1 / PD-L1 immune checkpoint & T-cell activation
Shares Give immunotherapy in the morning, Microbiome transplant as a routine immunotherapy adjunct, What actually holds T cells at the tumour border?, Microbiome–tumour interactions.
- InstitutionThe Royal Marsden
Shares A mandatory trial line in every tumour board recommendation, A global first-in-human network for academic cancer trials with single ethics review, Sarcomas (soft tissue, bone, GIST), Prostate cancer.